BR112014027087B1 - tablete e método para fabricação de um tablete de mesilato de bromocriptina - Google Patents

tablete e método para fabricação de um tablete de mesilato de bromocriptina Download PDF

Info

Publication number
BR112014027087B1
BR112014027087B1 BR112014027087-2A BR112014027087A BR112014027087B1 BR 112014027087 B1 BR112014027087 B1 BR 112014027087B1 BR 112014027087 A BR112014027087 A BR 112014027087A BR 112014027087 B1 BR112014027087 B1 BR 112014027087B1
Authority
BR
Brazil
Prior art keywords
tablet
bromocriptine mesylate
bromocriptine
mesylate
particle size
Prior art date
Application number
BR112014027087-2A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014027087A2 (pt
Inventor
Anthony H. Cincotta
Craig Michael Bowe
Paul Clark Stearns
Laura Jean Weston
Original Assignee
Veroscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veroscience Llc filed Critical Veroscience Llc
Publication of BR112014027087A2 publication Critical patent/BR112014027087A2/pt
Publication of BR112014027087B1 publication Critical patent/BR112014027087B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BR112014027087-2A 2012-04-30 2013-04-29 tablete e método para fabricação de um tablete de mesilato de bromocriptina BR112014027087B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/460,452 US8431155B1 (en) 2012-04-30 2012-04-30 Bromocriptine formulations
US13/460,452 2012-04-30
PCT/US2013/038655 WO2013165902A1 (en) 2012-04-30 2013-04-29 Bromocriptine formulations

Publications (2)

Publication Number Publication Date
BR112014027087A2 BR112014027087A2 (pt) 2017-06-27
BR112014027087B1 true BR112014027087B1 (pt) 2021-03-02

Family

ID=48146046

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014027087-2A BR112014027087B1 (pt) 2012-04-30 2013-04-29 tablete e método para fabricação de um tablete de mesilato de bromocriptina

Country Status (12)

Country Link
US (11) US8431155B1 (enExample)
EP (4) EP4342536B1 (enExample)
JP (1) JP6180515B2 (enExample)
KR (1) KR101593360B1 (enExample)
AR (1) AR091351A1 (enExample)
AU (3) AU2013256558B2 (enExample)
BR (1) BR112014027087B1 (enExample)
CA (1) CA2872300C (enExample)
ES (4) ES3050125T3 (enExample)
MX (2) MX363670B (enExample)
UY (1) UY34776A (enExample)
WO (1) WO2013165902A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
EP2217073B1 (en) 2007-06-21 2019-10-09 VeroScience LLC Method of treating metabolic disorders and depression with dopamine receptor agonists
US8741918B2 (en) 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
US8431155B1 (en) 2012-04-30 2013-04-30 Veroscience Llc Bromocriptine formulations
CA2866230C (en) 2012-05-03 2020-08-18 Janssen R&D Ireland Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections
WO2017184875A1 (en) * 2016-04-20 2017-10-26 Veroscience Llc Composition and method for treating metabolic disorders
US10426772B2 (en) 2016-05-16 2019-10-01 Regents Of The University Of Minnesota Use of ergot alkaloids as an anthelmintic agent
PL3697418T3 (pl) 2017-10-18 2025-02-03 Veroscience Llc Polepszone preparaty bromokryptyny
WO2021061818A1 (en) 2019-09-23 2021-04-01 Veroscience Llc Method for inducing tumor regression

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783469A (en) 1986-03-07 1988-11-08 Meier Albert H Method of inhibiting body fat stores
US4659715A (en) 1986-03-07 1987-04-21 Louisiana State University And Agricultural And Mechanical College Method of inhibiting body fat stores
US4791125A (en) 1987-12-02 1988-12-13 Pfizer Inc. Thiazolidinediones as hypoglycemic and anti-atherosclerosis agents
US5700800A (en) 1988-05-10 1997-12-23 Ergo Science Incorporated Methods for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates with a prolactin stimulatory compound
US5716933A (en) 1988-05-10 1998-02-10 Louisiana State University And Agricultural And Mechanical College Process for the long term reduction of body fat stores, insulin resistance, and hyperinsulinemia in vertebrates
US5344832A (en) 1990-01-10 1994-09-06 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates
US5668155A (en) 1988-05-10 1997-09-16 The General Hospital Corporation Administration of pirenzepine, methyl scopolamine and other muscarinic receptor antagonists for treatment of lipid metabolism disorders
US5744477A (en) 1988-05-10 1998-04-28 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for treatment of obesity using prolactin modulators and diet
US5468755A (en) 1988-05-10 1995-11-21 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of Type II diabetes
US5830895A (en) 1988-05-10 1998-11-03 The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods for the determination and adjustment of prolactin daily rhythms
US5585347A (en) 1988-05-10 1996-12-17 Ergo Science Incorporated Methods for the determination and adjustment of prolactin daily rhythms
US6004972A (en) 1988-05-10 1999-12-21 The Board Of Supervisiors Of Louisiana State University And Agricultural And Mechanical College Therapeutic process for the treatment of the pathologies of type II diabetes
US5006526A (en) 1988-10-17 1991-04-09 Louisiana State University Method of treating a vertebrate animal to reduce plasma triglycerides and cholesterol levels and to alleviate and prevent atherosclerosis
IT1235053B (it) * 1989-04-07 1992-06-17 Poli Ind Chimica Spa Metodi per la preparazione di composizioni farmaceutiche a base di bromocriptina dotate di elevata stabilita' e prodotti derivanti.
CA2030174C (en) 1990-01-10 1996-12-24 Anthony H. Cincotta Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hypoglycemia in vertebrates
US5696128A (en) 1994-07-07 1997-12-09 The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College Method of regulating immune function
IL112106A0 (en) 1993-12-22 1995-03-15 Ergo Science Inc Accelerated release composition containing bromocriptine
GB9421836D0 (en) 1994-10-28 1994-12-14 Scherer Corp R P Process for preparing solid pharmaceutical dosage forms of hydrophobic substances
US5565454A (en) 1995-05-31 1996-10-15 Ergo Science, Incorporated Method for preventing intervention-associated stenosis and other symptoms associated with stenosis of blood vessels following non-bypass, invasive interventions
US5714519A (en) 1995-06-07 1998-02-03 Ergo Science Incorporated Method for regulating glucose metabolism
US5626860A (en) 1995-06-07 1997-05-06 The Board Of Supervisors Of Louisana State And Agricultural And Mechanical College Method for regulating metabolism with dopamine beta hydroxylase inhibitors
US5792748A (en) 1995-06-07 1998-08-11 The General Hospital Corporation Method for inhibiting neoplastic disease in mammals
US20010016582A1 (en) 1997-04-28 2001-08-23 Anthony H. Cincotta Method and composition for the treatment of lipid and glucose metabolism disorders
US5877183A (en) 1996-06-06 1999-03-02 Ergo Research Corporation Treatment of lipid and glucose metabolism disorders with dopamine and serotonin agonists
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20040220190A1 (en) 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US20050054652A1 (en) 2002-07-29 2005-03-10 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US20040077679A1 (en) 2002-07-29 2004-04-22 Cincotta Anthony H. Therapeutic treatment for the metabolic syndrome and type 2 diabetes
US20040081678A1 (en) 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
US7119221B2 (en) 2003-01-23 2006-10-10 Esperion Therapeutics, Inc. Cycloalkyl-hydroxyl compounds and compositions for cholesterol management and related uses
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20050215558A1 (en) 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
US8137993B2 (en) 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US8137994B2 (en) 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
ATE430559T1 (de) 2005-03-04 2009-05-15 Nycomed Pharma As Verfahren zur herstellung von calciumzusammensetzungen im kontinuierlichen fliessbett
EP1968601B1 (en) * 2006-01-05 2011-10-19 Essentialis, Inc. Salts of potassium atp channel openers and uses thereof
WO2007119792A1 (ja) * 2006-04-13 2007-10-25 Toa Pharmaceuticals Co., Ltd. 乾式直打速崩壊性錠剤
CN101657186B (zh) 2007-04-13 2012-07-18 陶氏环球技术公司 剂型用粒状材料
US8741918B2 (en) 2007-06-21 2014-06-03 Veroscience Llc Parenteral formulations of dopamine agonists
US20210401824A1 (en) 2007-06-21 2021-12-30 Veroscience Llc Parenteral Formulations of Dopamine Agonists
EP2217073B1 (en) 2007-06-21 2019-10-09 VeroScience LLC Method of treating metabolic disorders and depression with dopamine receptor agonists
US20100035886A1 (en) 2007-06-21 2010-02-11 Veroscience, Llc Parenteral formulations of dopamine agonists
US7631155B1 (en) 2007-06-30 2009-12-08 Emc Corporation Thin provisioning of a file system and an iSCSI LUN through a common mechanism
WO2009048251A2 (en) * 2007-10-11 2009-04-16 Mazence Inc. Pharmaceutical composition containing micronized particles of naphthoquinone-based compound
EP2437732B1 (en) * 2009-06-05 2018-05-09 VeroScience LLC Combination of dopamine agonists plus first phase insulin secretagouges for the treatment of metabolic disorders
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders
US20130274246A1 (en) 2010-06-08 2013-10-17 Anthony H. Cincotta Therapeutic Treatment for Metabolic Syndrome, Type 2 Diabetes, Obesity, or Prediabetes
BR112013012212A2 (pt) 2010-11-23 2017-11-07 Veroscience Llc método para tratar doença renal crônica ou doenças degenerativas relacionadas à idade do paciente
US8431155B1 (en) 2012-04-30 2013-04-30 Veroscience Llc Bromocriptine formulations
JP2016521755A (ja) 2013-06-13 2016-07-25 ヴェロサイエンス，リミテッド・ライアビリティー・カンパニー 代謝障害を治療するための組成物および方法
WO2017184875A1 (en) 2016-04-20 2017-10-26 Veroscience Llc Composition and method for treating metabolic disorders
US20170340271A1 (en) 2016-05-26 2017-11-30 Veroscience Llc Methods for identifying responders to dopaminergic neuronal enhancing therapies for the treatment of elevated heart rate and metabolic or cardiovascular conditions
PL3697418T3 (pl) 2017-10-18 2025-02-03 Veroscience Llc Polepszone preparaty bromokryptyny
WO2021061818A1 (en) 2019-09-23 2021-04-01 Veroscience Llc Method for inducing tumor regression

Also Published As

Publication number Publication date
EP3620155A1 (en) 2020-03-11
MX363670B (es) 2019-03-29
US11666567B2 (en) 2023-06-06
US9522117B2 (en) 2016-12-20
AU2016202572A1 (en) 2016-05-19
AU2016202572B2 (en) 2018-02-01
US9993474B2 (en) 2018-06-12
US20210228576A1 (en) 2021-07-29
US20170340632A1 (en) 2017-11-30
CA2872300C (en) 2016-08-16
AR091351A1 (es) 2015-01-28
EP2844229B1 (en) 2019-09-11
KR101593360B1 (ko) 2016-02-11
US20160038424A1 (en) 2016-02-11
EP3960160A1 (en) 2022-03-02
EP4342536C0 (en) 2025-10-01
US9192576B2 (en) 2015-11-24
US20200276193A1 (en) 2020-09-03
US8613947B2 (en) 2013-12-24
ES3050125T3 (en) 2025-12-19
UY34776A (es) 2013-11-29
AU2018203021B2 (en) 2020-02-06
MX2019003619A (es) 2019-07-18
BR112014027087A2 (pt) 2017-06-27
US20240131026A1 (en) 2024-04-25
EP4342536A2 (en) 2024-03-27
US8431155B1 (en) 2013-04-30
EP4342536A3 (en) 2024-06-26
AU2013256558A1 (en) 2014-12-18
MX2014013158A (es) 2015-07-14
HK1208173A1 (en) 2016-02-26
AU2018203021A1 (en) 2018-05-24
EP3960160B1 (en) 2023-12-06
AU2013256558B2 (en) 2016-01-28
JP2015515984A (ja) 2015-06-04
WO2013165902A1 (en) 2013-11-07
KR20150006461A (ko) 2015-01-16
US20140187560A1 (en) 2014-07-03
CA2872300A1 (en) 2013-11-07
EP3620155B1 (en) 2021-10-20
US20170020871A1 (en) 2017-01-26
ES2902573T3 (es) 2022-03-29
US9700555B2 (en) 2017-07-11
US20130287848A1 (en) 2013-10-31
EP4342536B1 (en) 2025-10-01
US11000522B2 (en) 2021-05-11
JP6180515B2 (ja) 2017-08-16
EP2844229A1 (en) 2015-03-11
US20190343833A1 (en) 2019-11-14
ES2755081T3 (es) 2020-04-21
US10307421B2 (en) 2019-06-04
US20180263978A1 (en) 2018-09-20
US10688094B2 (en) 2020-06-23
ES2972198T3 (es) 2024-06-11

Similar Documents

Publication Publication Date Title
US11666567B2 (en) Bromocriptine formulations
HK40026299B (en) Bromocriptine formulations
HK40026299A (en) Bromocriptine formulations
HK1208173B (en) Bromocriptine formulations

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/04/2013, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 12A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2825 DE 25-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.